ILYX-002 is under clinical development by Iolyx Therapeutics and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ILYX-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ILYX-002 is under development for the treatment of keratoconjunctivitis sicca (dry eye disease), an ocular complication of autoimmune disease (OCAID). It is administered in the form of drops.
Iolyx Therapeutics overview
Iolyx Therapeutics engaged in research and development focused on autoimmunity and ophthalmology to offer novel treatments for ocular diseases. The company is headquartered in Menlo Park, California, the US.
For a complete picture of ILYX-002’s drug-specific PTSR and LoA scores, buy the report here.